RCM Tech | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 70.29 M

Revenue: As of FY2025 Q3, the actual value is USD 70.29 M, beating the estimate of USD 67.34 M.

EPS: As of FY2025 Q3, the actual value is USD 0.3, missing the estimate of USD 0.34.

EBIT: As of FY2025 Q3, the actual value is USD 3.908 M.

Segment Revenue

• Specialty Health Care: Revenue for the thirteen weeks ended September 27, 2025, was $30.0 million, compared to $26.6 million for the same period in 2024.
• Engineering: Revenue for the thirteen weeks ended September 27, 2025, was $31.4 million, compared to $24.2 million for the same period in 2024.
• Life Sciences, Data and Solutions: Revenue for the thirteen weeks ended September 27, 2025, was $8.9 million, compared to $9.6 million for the same period in 2024.

Operational Metrics

• Net Income: GAAP net income for the thirteen weeks ended September 27, 2025, was $2.3 million, compared to $2.7 million for the same period in 2024.
• Gross Margin: Gross profit margin for the thirteen weeks ended September 27, 2025, was 27.6%, compared to 29.6% for the same period in 2024.
• Operating Income: Operating income for the thirteen weeks ended September 27, 2025, was $3.9 million, compared to $4.4 million for the same period in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities for the thirteen weeks ended September 27, 2025, was - $1.3 million, compared to - $4.3 million for the same period in 2024.

Unique Metrics

• Adjusted EBITDA: Adjusted EBITDA for the thirteen weeks ended September 27, 2025, was $5.5 million, compared to $5.6 million for the same period in 2024.

Outlook / Guidance

• RCM Technologies expects the fourth quarter to yield the highest quarterly gross profit and adjusted EBITDA in fiscal 2025, with continued momentum heading into 2026.